Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Patients with metastasis prostate cancer underwent androgen deprivation therapy (ADT) in the considering of the leading role of androgen receptor pathway. However, the resistance occurred within 1 year or more. The combination of cytotoxic chemotherapy and abiraterone for ADT therapy was performed in recent randomized controlled trials. The meta-analysis was focused on the treatment comparisons between additional treatment with ADT and ADT alone. A significant difference was observed that the overall survival benefit of early and active additional treatment with ADT in patients with hormone-sensitive metastatic prostate cancer. However, a great proportion of patients with metastatic disease have metastases after receiving ADT. It will be important to further improve the treatment options.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2018-0619 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ASO Visual Abstract: The Effect of Chronic Liver Disease on Adverse In-Hospital Outcomes after Radical Cystectomy and Ileal Conduit Urinary Diversion.
Ann Surg Oncol
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, QC, Canada.
Cancer-specific mortality in secondary bladder cancer after nephroureterectomy for upper tract urothelial carcinoma.
Urol Oncol
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Objective: To examine differences in cancer-specific mortality (CSM) in nonmetastatic upper tract urothelial carcinoma (UTUC) patients with vs. without secondary bladder cancer (BCa) after radical nephroureterectomy (RNU).
Methods: Within the Surveillance, Epidemiology, and End Results database (SEER 2000-2021), T1-T4N0M0 UTUC patients treated with RNU and diagnosed with secondary BCa were identified.
Family History of Prostate, Breast, Ovarian, and/or Pancreatic Cancer and Associations with Grade Reclassification in a Large Prostate Cancer Active Surveillance Cohort.
Eur Urol Oncol
September 2025
The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:
Background And Objective: The effect of family history (FH) on prostate cancer active surveillance outcomes is unknown. Our objective is to evaluate FH of prostate, breast, ovarian, and/or pancreatic cancer in a large prospective active surveillance cohort.
Methods: Patients with recorded FH data (N = 1421) were selected.
Prophylactic Pelvic Nodal Radiation Therapy in High-risk Node-negative Prostate Cancer: The Case Against.
Int J Radiat Oncol Biol Phys
October 2025
Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.
Pelvic Nodal Irradiation Should Be Offered to High-Risk Prostate Cancer Patients Receiving Radiation Therapy.
Int J Radiat Oncol Biol Phys
October 2025
Division of Radiation oncology, Department of Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. Electronic address: